TCRX
TScan Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.31
−6.48%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 6.48x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.31x
- Price / sales
- 2.97x
- Price / cash flow
- -0.18x
Enterprise value
- Enterprise value
- $11.9M
- EV / sales
- 1.67x
- EV / EBITDA
- -0.11x
- EV / EBIT
- -0.10x
- Market cap
- $21.1M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026